Global Biosimilar Pipeline Flowing with Promise
While patents continue to clog the U.S. biosimilar pipeline, other countries are benefiting from an increasing flow of the discounted copies of complex biologics. Using a biosimilar pathway developed in 2012, India last week approved the first follow-on to pour from Mylan Inc.’s partnership with Indian drugmaker Biocon Ltd. – a biosimilar Herceptin (trastuzumab, Roche Group).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST